News | May 14, 2025
Bayer confirms 2025 targets after solid start to the year
EBITDA before special items decreases to €4.08 billion (7.4%)
EBITDA before special items decreases to €4.08 billion (7.4%)
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Subscribe To Our Newsletter & Stay Updated
